Thomas Burns Net Worth

The estimated Net Worth of Thomas M. Burns is at least $1.07 Million dollars as of 15 July 2022. Mr. Burns owns over 2,000 units of XOMA Royalty stock worth over $232,012 and over the last 9 years he sold XOMA stock worth over $29,043. In addition, he makes $813,210 as Chief Financial Officer and Senior Vice President - Finance at XOMA Royalty.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Burns XOMA stock SEC Form 4 insiders trading

Thomas has made over 10 trades of the XOMA Royalty stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of XOMA stock worth $8,060 on 15 July 2022.

The largest trade he's ever made was exercising 22,222 units of XOMA Royalty stock on 13 November 2017 worth over $89,555. On average, Thomas trades about 4,981 units every 100 days since 2016. As of 15 July 2022 he still owns at least 8,555 units of XOMA Royalty stock.

You can see the complete history of Mr. Burns stock trades at the bottom of the page.

Thomas Burns biography

Thomas Burns serves as Chief Financial Officer, Senior Vice President - Finance of the Company. Mr. Burns has been our Senior Vice President, Finance and Chief Financial Officer since March 2017. He joined the Company in August 2006 and since then has held various senior finance and accounting roles, most recently as Vice President, Finance and Chief Financial Officer. Mr. Burns has over 20 years of experience in accounting and finance in both biotechnology and high-technology companies. Prior to his employment with the Company, he held multiple senior financial management positions at high-tech companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner Technology. Mr. Burns received his Bachelor’s degree from Santa Clara University and his Masters of Business Administration from Golden Gate University.

What is the salary of Thomas Burns?

As the Chief Financial Officer and Senior Vice President - Finance of XOMA Royalty, the total compensation of Thomas Burns at XOMA Royalty is $813,210. There are 1 executives at XOMA Royalty getting paid more, with James Neal having the highest compensation of $1,479,560.

How old is Thomas Burns?

Thomas Burns is 46, he's been the Chief Financial Officer and Senior Vice President - Finance of XOMA Royalty since 2015. There are 8 older and no younger executives at XOMA Royalty. The oldest executive at XOMA Royalty Corp. is W. Denman Van Ness, 77, who is the Independent Chairman of the Board.

What's Thomas Burns's mailing address?

Thomas's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC., 2 BLUE HILL PLAZA, 3RD FLOOR, PEARL RIVER, NY, 10965.

Insiders trading at XOMA Royalty

Over the last 21 years, insiders at XOMA Royalty have traded over $74,428,857 worth of XOMA Royalty stock and bought 6,217,869 units worth $44,091,555 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Bros. Advisors Lp667, L.P.B.... On average, XOMA Royalty executives and independent directors trade stock every 31 days with the average trade being worth of $3,397,377. The most recent stock trade was executed by Owen Hughes on 2 October 2023, trading 1,000 units of XOMA stock currently worth $13,830.

What does XOMA Royalty do?

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Complete history of Mr. Burns stock trades at Acorda Therapeutics Inc and XOMA Royalty

XOMA Royalty executives and stock owners

XOMA Royalty executives and other stock owners filed with the SEC include:

• James Neal,
  Chief Executive Officer, Director
• Thomas Burns,
  Chief Financial Officer, Senior Vice President - Finance
• James R. Neal,
  CEO & Chairman
• Thomas M. Burns,
  Sr. VP of Fin. & CFO
• Barbara Kosacz,
  Independent Director
• W. Denman Van Ness,
  Independent Chairman of the Board
• Jack Wyszomierski,
  Independent Director
• Joseph Limber,
  Independent Director
• Matthew Perry,
  Independent Director
• Natasha Hernday,
  Director
• Deepshikha Datta,
  Chief Business Officer
• Timothy P Walbert,
  Director
• Peter Barton Hutt,
  Director
• Paul D Rubin,
  VP Clinical Dev. & CMO
• Steven B Engle,
  CEO and President
• Charles J Jr Fisher,
  Director
• Patrick J Zenner,
  Director
• John Varian,
  Director
• Owen Hughes,
  Chief Executive Officer
• Partners L P/Ilbiotechnolog...,
  
• Fred Kurland,
  VP Finance
• Thomas Klein,
  Chief Commercial Officer
• William K Jr Bowes,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lpbaker Feli...,
  
• Bros Advisors Llcbaker Feli...,
  
• Patrick J Md Phd Scannon,
  CSMO
• Kelvin Neu,
  Director
• Julianbaker Bros Advisors L...,
  
• J David Ii Boyle,
  VP, Finance, and CFO
• Arthur Md Kornberg,
  Director
• John L Castello,
  Chairman, CEO & President
• James G Andress,
  Director
• Peter B Davis,
  VP, Finance & CFO
• Clarence L Dellio,
  Sr VP, Operations and COO
• Steven C Mendell,
  Director
• Christopher J Margolin,
  VP, General Counsel & Sec'y
• Partners L P/Ilbiotechnolog...,
  
• Heather L Franklin,
  
• Bradley Sitko,
  Chief Investment Officer